As cell and gene therapies move from early development toward clinical and commercial production, manufacturers face growing pressure to improve scalability, reliability, and speed. In a recent GEN article, SK pharmteco shares insights on the next wave of improvements shaping CGT manufacturing scale-up—from optimized lentiviral vector production to integrated solutions that help developers reduce risk as programs advance.
With global capabilities across the U.S., Europe, and South Korea, SK pharmteco supports biopharmaceutical partners with specialized development and manufacturing expertise for complex therapies. Recent investments, including commercial-scale viral vector capacity in France and expanded plasmid manufacturing capabilities in King of Prussia, strengthen SK pharmteco’s ability to support CGT developers from early-stage development through late-stage and commercial supply.
Read the GEN article to learn how innovation in viral vectors, plasmids, and scalable manufacturing platforms is helping advance the future of cell and gene therapy.